Boyle Transportation is now part of Marken Precision Logistics, bringing more than 50 years of experience moving critical healthcare shipments across North America as an asset-based, specialist healthcare carrier.
We spoke to Dan Bell, SVP, Drug Supply, Storage & Distribution and Advanced Therapy Logistics, about why Boyle is such a strong fit, what it means for customers and where the combined business goes next.
What’s your personal take on Boyle becoming part of Marken Precision Logistics?
When I was asked to lead this, I was really excited. To be honest, I've known Boyle for a really long time as a quality focused company. They're absolutely at the top-tier. I had several clients come up to me at a recent industry cold chain event and say, "Boyle is great. You really picked a good one," or "I'm so glad you guys are involved, because they fit really well with what you're already doing."
People already know the high-quality and precision-driven transport they're capable of. That's important not just for our clients and potential clients, but for us as well.
What makes Boyle different from other carriers?
There are some things that are really fundamental here. First, we now have an asset-based, long-haul trucking carrier in North America. By asset-based, I mean Boyle’s drivers are employees who drive tractors and trailers that we own. That’s an important distinction. Most 3PL, and even 4PL, is about how you contract third parties to do that for you, and some providers use brokered freight.
Boyle has a really well-established pedigree when it comes to requirements associated with transporting regulated materials. In particular, cold-chain pharma logistics, which covers pharma clients and all of the support players in that arena, like CDMOs and CROs.
For example, we don’t have to teach Boyle the principles of Good Distribution Practice. They were early pioneers in that space. The mapping, the temperature-controlled trailers, and understanding the requirements for those types of products are ingrained in their knowledge and expertise.
What sets Boyle’s drivers apart?
Just like Marken, they’ve invested heavily in the training of their professional drivers. A huge part of their program isn’t teaching drivers how to drive a truck. It’s teaching them why what they’re carrying, mostly drugs, blood plasma, and other therapeutics, makes their job different by contributing to the health of patients.
There are all sorts of stats about the market: whether there are going to be enough drivers, or whether they’ll be replaced by autonomous trucks. But at the end of the day, it won’t be who’s got the shiniest truck or who’s got the best tracking device. It’ll literally be down to the attitude and the quality of the professional drivers that you have.
There’s a lot to be said for employee-operated transport versus contracted. Boyle drivers are not looking for the next gig. They know what their work is, they know what their hours are, and they’re going to get paid for it. So, they can take the time to make good decisions.
Everyone has a friend, family member, or colleague impacted by something in healthcare. Boyle was one of the first choices to handle the transportation of vaccines in North America during the COVID era. Their trucks carry life-saving therapies. They know that what they’re moving has a huge impact.
We also asked Rick Araniz, President of Boyle Transportation, what joining Marken means for Boyle’s drivers.
"When our drivers asked what joining Marken means for them, my answer was simple: Marken shares the same values of professionalism and dedication to safety and quality. Marken, like Boyle, has demonstrated a continued commitment to excellence and remaining as the premier provider and industry leader on which patients and their families can depend.
Our drivers understand how critical the mission we perform each day is, and that they are the vital key. They know it is “not a pallet, but a patient.” Our drivers, along with all of their Boyle colleagues, take pride in the work they perform and are excited that joining Marken provides a much bigger network behind them, and more ways for their expertise to reach patients."
— Rick Araniz, President, Boyle Transportation
What does Boyle joining Marken mean for customers?
What remains consistent is our approach to quality. Our way of thinking about and dealing with quality is aligned with pharma, not with transport. The way we approach investigations and CAPAs, the way we run our QMS. It’s not just about being GDP compliant. It’s about being at the same level as the companies producing the product, and Boyle shares that approach.
Where customers will see added value is connectivity. Having an asset-based carrier allows us to be both flexible and competitive. It also gives us a well-integrated, connected capability that helps us deliver on the supply chain promise we make to our clients. When you’re trying to piece together various players in a supply chain, having part of the family do that for you is infinitely easier, and you can come up with more creative solutions for clients.
For example, if you were a German company making API for a US-based sponsor, you could fly your pallets from Frankfurt on a UPS aircraft into the US. It could be met by a Boyle truck and taken to a CDMO to be labeled, then transported by that same trucking company to a depot that Marken runs, ready to be distributed. It links everything up.
As an enterprise, UPS Healthcare already has well-established connections with those companies. When I walk into a meeting to have a strategic conversation, I can pull all of those things together and know exactly what we’re doing across the enterprise. I don’t think anybody else can offer that. It’s really unique.
How does Boyle protect temperature-sensitive products on the road?
First of all, there’s the thermal mapping of trailers. Then there’s the ability to monitor constantly. Temperature and GPS location are monitored remotely, and there are cameras and multiple monitoring systems in every vehicle and trailer. Their transportation management system allows them to step in and rescue a shipment if that ever becomes the case.
The reality is that many temperature excursions happen at handoffs. At airports there’s always a handoff, because shipments don’t stay on the plane. They end up going into trucks. So, at those handoffs, you want expertise in loading and unloading the truck. Boyle has that experience and the equipment to do it: not just the trailer, which protects the product thermally, but also the monitoring.
Visibility through technology is only valuable if you have a plan to act on it. Otherwise, it’s just observation. Boyle has both. The technology to see what’s happening, and the expertise and contingency plans to act on it.
Where does Boyle fit as therapies move from clinical to commercial?
From clinical to commercialization, there are some real advantages to having an asset-based fleet that allows you to scale up. Long-haul trucking probably isn’t relevant for one box of clinical drugs going to a clinical site. But as you work on the elements of drug supply and distribution, it becomes increasingly relevant.
With advanced therapies, the big opportunity is in therapies based on RNA and in allogeneic cell and gene therapies, rather than autologous ones. Autologous is vein-to-vein. It starts with the patient and goes back to the patient, so it’s one box at a time. Allogeneic is one to many. You could have thousands of doses, ultimately millions of doses, going out, and the same is true of RNA therapies and vaccines. That’s where Boyle can have the biggest impact. They’ve already proven themselves more than capable during COVID, and they’re still heavily involved in commercial vaccine distribution.
Something that’s really interesting is the specialist transportation of radiopharmaceuticals. As many of those products go from phase II to III, and from III into commercialization, Boyle will have a strong part to play. Marken now has the special permits required for the transport of radiopharmaceuticals in the US, and Boyle can also carry Class 7 materials, fully licensed and accredited for that type of transportation.
Boyle also plays very strongly in the manufacturing supply chain. All of these products have to be made somewhere, and the excipients, APIs and temperature-controlled materials that go into them all need to move. Then there’s plasma, where they’ve got a ton of expertise, with the cold chain, multi-chamber trailers and liftgates that work needs.
Why does security matter more than ever, and where does Boyle help?
Clinical studies are not usually the target of theft, but commercialized drugs are. GLP-1s in particular. Then there’s the whole issue of falsified or adulterated medicine, which is what DSCSA addresses. It’s a big deal.
At a recent industry event, a speaker from a major plasma company presented on how sophisticated AI has become. Because your voice is out there, it can be simulated to divert drivers. You can simulate the dispatcher. He said AI is a hammer. It can either build a house or smash it down.
So, security matters a lot, especially when it comes to very desirable products like GLP-1s. We can’t tell people how we do it, but having a carrier with real expertise in that area is an important part of how you manage it.
What comes next for Boyle within Marken Precision Logistics?
Looking ahead, the next opportunity is taking Boyle’s existing model, which works very well over the road, and leveraging their transport management system, expertise and know-how into models that are more localized around population densities. That means local teams, where everything is done within a day. That's a good one for plasma, but it also works for nuclear medicine. And Marken is always looking at opportunities to take our expertise to the rest of the world.